Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
IJU Case Reports|July 14, 2021
Granulomatous prostatitis with high suspicion of prostatic adenocarcinoma on radiological imagingYoshiki Ambe, Masaki Nakamura, Norihide Shirakawa, et al.
International Journal of Clinical Oncology|June 17, 2021
Assessment of surgical outcomes of off-clamp open partial nephrectomy without renorrhaphy for ≥T1b renal tumoursMasaki Nakamura, Yoshiki Ambe, Taro Teshima, et al.
Translational Andrology and Urology|October 11, 2022
Predictive factors for postoperative renal function after off-clamp, non-renorrhaphy partial nephrectomyMasaki Nakamura, Shuji Kameyama, Yoshiki Ambe, et al.
International Journal of Clinical Oncology|March 3, 2025
The first real-world evidence on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin followed by switch maintenance avelumab in advanced urothelial carcinoma: a propensity score-matched studySatoru Taguchi, Taketo Kawai, Yoshiaki Kurokawa, et al.
Japanese Journal of Clinical Oncology|January 15, 2025
Optimization of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy for Japanese patients with urothelial carcinomaTaketo Kawai, Yoshiaki Kurokawa, Satoru Taguchi, et al.
Japanese Journal of Clinical Oncology|June 27, 2025
Predictive ability of the geriatric 8 screening tool for treatment completion of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy in patients with urothelial carcinomaYoshiaki Kurokawa, Taketo Kawai, Satoru Taguchi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 23, 2023
Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched studySatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|November 22, 2024
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysisSatoru Taguchi, Taketo Kawai, Yoshiki Ambe, et al.
Pageof 1